The global Orally Disintegrating Tablets Market was valued at USD 11,988 Million in 2019 and is projected to reach USD 25,820 Million by 2027, expanding at a CAGR of 10.18% during the forecast period. The demand for orally disintegrating tablets is growing as ageing population due to increased life expectancy in rising in many countries. Moreover, Growing awareness among people regarding the availability of advance therapies is expected to boost the demand for advanced dosage form in developing countries. Additionally, Growing demand for multivitamins is expected to create lucrative opportunities for manufacturers in the market.
Aging population is increasing due to rising life expectancy. Moreover, availability of advance medical facilities and advancements in medical science have increased the survival rate of people suffering from chronic diseases. Oral disintegrating tablets is an ideal solution for the elderly, which helps them to complete a drug course. This, in turn, is expected to propel the market growth. Moreover, ODTs are suitable dosage forms prescribed for mentally disabled people, as compared to other dosage forms. It is easy to guide such people to take this dosage form, as it has fast onset of action, which provides them quick relief. Growing adoption of oral disintegrating tablets for the treatment of various conditions in mentally disabled is expected to boost the market. Furthermore, People suffering from various diseases such as Parkinson’s, Alzheimer's, lung diseases, kidney diseases, diabetes, stroke, heart diseases, and allergies, and GI disorders need to take various medications for a long period of time. Doctors prescribe oral medications to patients for post-operative care. Oral disintegrating tablets are ideal solutions for people, which disintegrates quickly and provides desired therapies with high patient compliance. Oral route of administration is convenient and acceptable dosage form for patients and physicians. Oral route administration with fast onset of action boosts the demand for ODT, which has ability to dissolve within a minute. These factors are expected to boost the ODT market growth.
However, Product recalls of ODTs by some manufacturers due to particular reasons is expected to hamper the market. For example, Impax Laboratories recalled one lot of lamotrigine orally disintegrating tablet 200 mg indicated for the treatment of epilepsy or bipolar disorders. Such increase in product recalls is expected to hinder the market. Additionally, ODTs can cause various side effects such as headaches, constipation, weakness, tiredness, dizziness, chills, loss of coordination, and drowsiness. In some conditions, it is important to inform the physician about other medications, if a person is taking along with a prescribed treatment to avoid the drug interactions, as it can led to serious side-effects.
Rising adoption of technologically advanced products and dosage forms for advanced treatment options in developing economies are expected to boost the demand for ODTs during the forecast period. Access to healthcare and improving the quality of care in developing countries are expected to create lucrative opportunities for manufacturers in these countries.
By Drug Class Segment
On the basis of drug class, the orally disintegrating tablets market is divided into anti-psychotics, anti-epileptic’s, CNS stimulants, anxiolytics, anti-parkinsonian drugs, anti-hypertensive, NSAIDS, anti-allergy drug, proton pump inhibitor, vaccine ODT, and others. The anti-psychotics segment is expected to hold xx% share of the market in 2020. The anti-parkinsonian drugs segment is anticipated to expand at a CAGR of xx% during the forecast period. Growing prevalence of psychotic disorder such as schizophrenia and bipolar disorder is projected to increase the demand for anti-psychotic drugs. Moreover, growing prevalence of Parkinson is expected to boost the demand for anti-parkinsonian drugs. ODT prescribed in the drugs class including anti-psychotics and anti-parkinsonian drugs. ODT is a widely preferred dosage form, as it provides fast effect owing to its quick disintegration, thus leading to high patient compliance.
By Disease Indication Segment
Based on disease indication, the market is segregated into central nervous system diseases (CNS), gastrointestinal (GI) diseases, cardiovascular (CVS) diseases, allergy, and others. The central nervous system diseases segment is estimated to account for significant market share in 2020, owing to increasing prevalence of CNS diseases globally. The cardiovascular (CVS) diseases segment is anticipated to expand at an accountable CAGR of during the forecast period. Growing prevalence of CNS and CVS diseases is expected to boost the demand for oral disintegrating tablets.
Asia Pacific is expected to remain a highly attractive region for the orally disintegrating tablets market and is projected to expand at a high CAGR during the forecast period. The region is expected to dominate the global market, in terms of value and volume, due to the use of ODTs to reduce the prevalence of various disorders such as CND, GI disorders, CVDs, and allergies. Growing population in the region and large presence of key players operating the market are major factors that are expected to increase the demand for ODTs in the region. High patient compliance and awareness among patients about availability of such dosage forms and low cost of oral disintegrating tablets have increased the preference for ODTs in the region.
The orally disintegrating tablets market in North America is expected to grow at a significant pace during the forecast period, owing to the rise in prevalence of diseases associated with the CNS. Alzheimer's disease, Bell's palsy, epilepsy, and Parkinson's disease are some CNS diseases. According to Alzheimer's Association a voluntary health organization in Alzheimer's care, an estimates 5.8 million people in the US, aged 65 and above are suffering from Alzheimer's disease in 2020, and this number is anticipated to reach by 13.8 million by 2050. Growing adoption of technologically advanced products is boosting the growth of the market in the region. Moreover, presence of key market players in the region is expected to boost the market in North America during the forecast period.
Some frequently asked quetions about this report!
Additional company profiles can be provided on request.
Yes, the report covers types of orally disintegrating tablets such as Antipsychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, Antiparkinsonian Drugs, Anti-Hypertensive, NSAIDS, Anti-Allergy Drugs, Proton Pump Inhibitors, Vaccine ODT and Others.
According to this Growth Market Reports report, the market from orally disintegrating tablets market is likely to register a CAGR of 10.18% during forecast period 2020-2027, with an anticipated valuation of USD 25,820 million by the end of the 2027.
In addition to market size (in USD Million) and Company Market Share (in % for base year 2019), other data such Macro-economic factors, COVID-19 Impact on the orally disintegrating tablets market is available in final report.
The orally disintegrating tablets market is anticipated to grow significantly during forecast period due to rising awareness about healthy lifestyle. Moreover, due to increasing number of diseases and rising old age population.
Central nervous system (CNS), diseases gastrointestinal (GI) diseases, cardiovascular diseases (CVDs), allergy, and other factors are the key applications driving the market growth.
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
The market is expected to witness growth with slight increase in terms of demand during 2019-2020 owing to the positive impact of COVID-19 pandemic on the orally disintegrating tablets market.
The base year considered for the global orally disintegrating tablets market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017 & 2018 are the historic years and the forecast is provided from 2020 to 2027.
Major Manufactures include Alkem Labs, Amneal Pharmaceuticals LLC, Apotex Inc., Aurobindo Pharma, Bausch Health Companies Inc., Eli Lilly and Company, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Viatris Inc. (Mylan N.V. and Pfizer's Upjohn).
Some other reports from this category!